Mirabegron Can Be Stopped Abruptly Without Tapering
If mirabegron (Myrbetriq) is ineffective for overactive bladder, you can discontinue it abruptly—no taper is required. Unlike medications that require gradual withdrawal to prevent rebound symptoms or withdrawal syndromes, mirabegron (a β3-adrenoceptor agonist) does not necessitate tapering when discontinued.
Why No Taper Is Needed
The FDA drug label for mirabegron does not specify any tapering requirements for discontinuation 1. This is consistent with the pharmacologic profile of β3-adrenoceptor agonists, which do not produce the same dependency or rebound phenomena seen with:
- Antimuscarinics (which can cause rebound worsening of OAB symptoms if stopped abruptly)
- Benzodiazepines (which require tapering to avoid withdrawal seizures)
- Antipsychotics (which may cause rebound tics or psychosis)
- SSRIs (which can cause discontinuation syndrome)
General medication discontinuation principles suggest that gradual tapering is primarily reserved for medications that cause withdrawal symptoms or rebound worsening 2, 3. Mirabegron does not fall into these categories.
What to Do When Mirabegron Fails
When mirabegron proves ineffective, the 2015 AUA/SUFU guidelines provide clear direction 4:
Don't abandon pharmacotherapy prematurely: Try switching to an antimuscarinic agent (tolterodine, solifenacin, fesoterodine, etc.) as these have similar efficacy profiles but different mechanisms of action and side effect profiles 5, 4
Consider dose modification first: Before completely stopping, evaluate whether the patient was on an adequate dose (50 mg is the standard effective dose in adults) 6
Reassess after 4-8 weeks: This is the minimum trial period to determine true treatment failure 4
Combine with behavioral therapy: If not already implemented, add bladder training or pelvic floor muscle training, which have high-quality evidence for efficacy 5
Practical Discontinuation Approach
Simply stop the medication. No dose reduction schedule is needed. However:
- Monitor for symptom return over the next 2-4 weeks to establish baseline severity before starting alternative therapy
- Check blood pressure if it was elevated on mirabegron, as BP should normalize after discontinuation 1
- Document the trial including dose, duration, and reason for discontinuation to guide future treatment decisions
Common Pitfall to Avoid
The main error is giving up on pharmacotherapy entirely after one medication fails. The 2014 ACP guidelines emphasize that different OAB medications have similar efficacy but variable tolerability profiles 5. A patient who doesn't respond to mirabegron may respond well to an antimuscarinic, and vice versa. The guidelines specifically state clinicians "should not abandon anti-muscarinic therapy if trial of one medication appears to fail" 4—this principle applies equally to β3-agonists.
Special Consideration for Pediatric Patients
Emerging evidence suggests that in children with neurogenic detrusor overactivity, there may be value in gradual withdrawal strategies 7. However, this research is ongoing and specific to the pediatric neurogenic population, not applicable to typical adult OAB patients where abrupt discontinuation remains appropriate.